Skip to Content
Morningstar

Qiagen NV QGEN

Morningstar Rating
Unlock
Stock XNYS Rating as of
$41.10 +0.52 (1.28%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Qiagen Still Pushing for Higher Growth Than Its End Markets

Julie Utterback

Qiagen aims to help scientists and caregivers use biological samples to identify and solve problems related to DNA, RNA, and proteins, which should remain in high demand even after the pandemic, albeit probably at a reset rate following that unique event. Qiagen's roots are in products that help scientists prepare biological samples for various experiments, and sample preparation products account for nearly 35% of sales. Qiagen remains a key leader in this niche, and we expect Qiagen to continue to invest to maintain or improve in that business in the long run.

Read Full Report

Price vs Fair Value

View History
QGEN is trading at a 91% premium.
Price
$41.10
Fair Value
$36.00
Uncertainty
Medium
1-Star Price
$46.10
5-Star Price
$68.10
Economic Moat
Qwt
Capital Allocation
Dykyxjhw

Bulls Say, Bears Say

Bulls

Qiagen’s long-term growth prospects in the life science and diagnostic markets will not dissolve after the pandemic.

Bears

Competitive threats in Qiagen's chosen fields, particularly diagnostics, may always remain high given the risk of disruptive innovation from new and established organizations.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if QGEN is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$40.58
Day Range
$40.77–41.23
52-Week Range
$35.81–49.18
Bid/Ask
$40.30 / $41.59
Market Cap
$9.12 Bil
Volume/Avg
804,010 / 1.1 Mil

Key Statistics

Price/Earnings (Normalized)
20.04
Price/Sales
4.72
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Small Core
Total Number of Employees
5,900
Website
https://www.qiagen.com

Competitors

Valuation

View More
Metric
QGEN
ILMN
TMO
Price/Earnings (Normalized)
 20.04123.3224.98
Price/Book Value
 2.533.014.53
Price/Sales
 4.723.824.92
Price/Cash Flow
 14.0436.8524.09
Price/Earnings
No chart available

Financial Strength

Metric
QGEN
ILMN
TMO
Quick Ratio
 1.211.181.19
Current Ratio
 1.841.751.70
Interest Coverage
 8.00−15.224.83
Quick Ratio
No chart available

Profitability

Metric
QGEN
ILMN
TMO
Return on Assets (Normalized)
 5.68%1.28%8.69%
Return on Equity (Normalized)
 9.46%2.25%18.71%
Return on Invested Capital (Normalized)
 6.07%1.78%10.97%
Return on Assets
No chart available
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Diagnostics & Research Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Thermo Fisher Scientific Inc
TMO
GhfcydwynMbl$206.2 Bil
 Danaher Corp
DHR
KqbrptbskbVflbv$177.2 Bil
 IDEXX Laboratories Inc
IDXX
VggbchbtMhtqxh$40.1 Bil
 IQVIA Holdings Inc
IQV
QkfkdvfvCvrdfgm$37.9 Bil
 Agilent Technologies Inc
A
NkpxnwtmpWxkhs$36.9 Bil
 Mettler-Toledo International Inc
MTD
DbysxmqkwTcywdpq$28.7 Bil
 Icon PLC
ICLR
TbprjrtfrSrfgr$26.6 Bil
 Illumina Inc
ILMN
TktmkntPvzsqvb$17.3 Bil
 Labcorp Holdings Inc
LH
GswqptkhPyzwqm$17.2 Bil
 Waters Corp
WAT
FxyhbgctQyy$17.0 Bil

Sponsor Center